Last reviewed · How we verify
Flonoltinib Maleate
Flonoltinib maleate is a tyrosine kinase inhibitor that targets the BCR-ABL1 protein.
Flonoltinib maleate is a tyrosine kinase inhibitor that targets the BCR-ABL1 protein. Used for Chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
At a glance
| Generic name | Flonoltinib Maleate |
|---|---|
| Sponsor | Chengdu Zenitar Biomedical Technology Co., Ltd |
| Drug class | tyrosine kinase inhibitor |
| Target | BCR-ABL1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
It works by selectively inhibiting the BCR-ABL1 protein, which is responsible for the proliferation of cancer cells in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). This inhibition leads to the suppression of cancer cell growth and proliferation.
Approved indications
- Chronic myeloid leukemia (CML)
- Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
Common side effects
- Myelosuppression
- Fatigue
- Nausea
Key clinical trials
- Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera (PHASE2)
- A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis (PHASE3)
- A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Medium to High Risk Myelofibrosis (PHASE2)
- Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative (PHASE1, PHASE2)
- A Pharmacokinetic Study of the Food Effect on Flonoltinib Maleate Tablets (PHASE1)
- A Phase I Clinical Study of Flonoltinib Maleate Tablets in Healthy Subjects (PHASE1)
- A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis (PHASE2)
- Study of Flonoltinib Maleate Tablets in the Treatment of Severe Novel Coronavirus (COVID-19) Infection (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flonoltinib Maleate CI brief — competitive landscape report
- Flonoltinib Maleate updates RSS · CI watch RSS
- Chengdu Zenitar Biomedical Technology Co., Ltd portfolio CI